Gain Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 4.01 million compared to USD 5.14 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.43 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.28 USD | +2.40% | -0.78% | -60.80% |
06-28 | Sector Update: Health Care Stocks Higher Pre-Bell Friday | MT |
06-27 | Gain Therapeutics Names Gene Mack as Interim Chief Executive Officer | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.80% | 32.22M | |
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.65% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- GANX Stock
- News Gain Therapeutics, Inc.
- Gain Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024